94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Siddhi N. Paudel1*Brian J. Hutzen1
Katherine E. Miller2,3Elizabeth A. R. Garfinkle2Chun-Yu Chen1
Pin-Yi Wang1Andrea M. Glaspell1Mark A. Currier1Emily M. Ringwalt1Louis Boon4Elaine R. Mardis2,3
Mitchell S. Cairo5Nancy Ratner6
Rebecca D. Dodd7Kevin A. Cassady1,3
Timothy P. Cripe1,3,8- 1Center for Childhood Cancer Research, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
- 2Institute for Genomic Medicine, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
- 3Department of Pediatrics, The Ohio State University Wexner College of Medicine, Columbus, OH, United States
- 4JJP Biologics, Warsaw, Poland
- 5Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology, and Cell Biology, New York Medical College, Valhalla, NY, United States
- 6Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
- 7Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, United States
- 8Division of Pediatric Hematology/Oncology/BMT, Nationwide Children’s Hospital, Columbus, OH, United States
by Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen C-Y, Wang P-Y, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA and Cripe TP (2024) 15:1384623. doi: 10.3389/fimmu.2024.1384623
In the published article, there was an error in the legend for Figure 1 as published. We mistaken referred to the tumor models as xenografts instead of syngeneic models in the sentence: “We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST xenografts.”
The corrected legend appears below.
The experimental design used in this report. We first compared different oHSV constructs for their ability to kill MPNST cells and shrink MPNST syngeneic tumors. As none of the viruses was consistently superior to the others, we chose the FDA-approved virus, T-VEC, to further study in combination with drugs postulated to enable viroimmunotherapy. Because in other studies we found trabectedin to be toxic to C57Bl/6 animals, we pivoted to an MPNST model in the Balb/c background to test that combination.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: malignant peripheral nerve sheath tumors, immunotherapy, tumor microenvironment, oncolytic virotherapy, macrophage targeting, trabectedin, pexidartinib, T-VEC
Citation: Paudel SN, Hutzen BJ, Miller KE, Garfinkle EAR, Chen C-Y, Wang P-Y, Glaspell AM, Currier MA, Ringwalt EM, Boon L, Mardis ER, Cairo MS, Ratner N, Dodd RD, Cassady KA and Cripe TP (2024) Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors. Front. Immunol. 15:1456897. doi: 10.3389/fimmu.2024.1456897
Received: 29 June 2024; Accepted: 01 July 2024;
Published: 09 July 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Paudel, Hutzen, Miller, Garfinkle, Chen, Wang, Glaspell, Currier, Ringwalt, Boon, Mardis, Cairo, Ratner, Dodd, Cassady and Cripe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Siddhi N. Paudel, cGF1ZGVsc2lkZGhpQGdtYWlsLmNvbQ==